Cargando…

High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis

To test the carcinostatic effects of ascorbic acid, we challenged the mice of seven experimental groups with 1.7 × 10(-4 )mol high dose concentration ascorbic acid after intraperitoneal administrating them with sarcoma S-180 cells. The survival rate was increased by 20% in the group that received hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeom, Chang-Hwan, Lee, Gunsup, Park, Jin-Hee, Yu, Jaelim, Park, Seyeon, Yi, Sang-Yeop, Lee, Hye Ree, Hong, Young Seon, Yang, Joosung, Lee, Sukchan
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732919/
https://www.ncbi.nlm.nih.gov/pubmed/19671184
http://dx.doi.org/10.1186/1479-5876-7-70
_version_ 1782171083852480512
author Yeom, Chang-Hwan
Lee, Gunsup
Park, Jin-Hee
Yu, Jaelim
Park, Seyeon
Yi, Sang-Yeop
Lee, Hye Ree
Hong, Young Seon
Yang, Joosung
Lee, Sukchan
author_facet Yeom, Chang-Hwan
Lee, Gunsup
Park, Jin-Hee
Yu, Jaelim
Park, Seyeon
Yi, Sang-Yeop
Lee, Hye Ree
Hong, Young Seon
Yang, Joosung
Lee, Sukchan
author_sort Yeom, Chang-Hwan
collection PubMed
description To test the carcinostatic effects of ascorbic acid, we challenged the mice of seven experimental groups with 1.7 × 10(-4 )mol high dose concentration ascorbic acid after intraperitoneal administrating them with sarcoma S-180 cells. The survival rate was increased by 20% in the group that received high dose concentration ascorbic acid, compared to the control. The highest survival rate was observed in the group in which 1.7 × 10(-4 )mol ascorbic acid had been continuously injected before and after the induction of cancer cells, rather than just after the induction of cancer cells. The expression of three angiogenesis-related genes was inhibited by 0.3 times in bFGF, 7 times in VEGF and 4 times in MMP2 of the groups with higher survival rates. Biopsy Results, gene expression studies, and wound healing analysis in vivo and in vitro suggested that the carcinostatic effect induced by high dose concentration ascorbic acid occurred through inhibition of angiogenesis.
format Text
id pubmed-2732919
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27329192009-08-28 High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis Yeom, Chang-Hwan Lee, Gunsup Park, Jin-Hee Yu, Jaelim Park, Seyeon Yi, Sang-Yeop Lee, Hye Ree Hong, Young Seon Yang, Joosung Lee, Sukchan J Transl Med Research To test the carcinostatic effects of ascorbic acid, we challenged the mice of seven experimental groups with 1.7 × 10(-4 )mol high dose concentration ascorbic acid after intraperitoneal administrating them with sarcoma S-180 cells. The survival rate was increased by 20% in the group that received high dose concentration ascorbic acid, compared to the control. The highest survival rate was observed in the group in which 1.7 × 10(-4 )mol ascorbic acid had been continuously injected before and after the induction of cancer cells, rather than just after the induction of cancer cells. The expression of three angiogenesis-related genes was inhibited by 0.3 times in bFGF, 7 times in VEGF and 4 times in MMP2 of the groups with higher survival rates. Biopsy Results, gene expression studies, and wound healing analysis in vivo and in vitro suggested that the carcinostatic effect induced by high dose concentration ascorbic acid occurred through inhibition of angiogenesis. BioMed Central 2009-08-11 /pmc/articles/PMC2732919/ /pubmed/19671184 http://dx.doi.org/10.1186/1479-5876-7-70 Text en Copyright © 2009 Yeom et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Yeom, Chang-Hwan
Lee, Gunsup
Park, Jin-Hee
Yu, Jaelim
Park, Seyeon
Yi, Sang-Yeop
Lee, Hye Ree
Hong, Young Seon
Yang, Joosung
Lee, Sukchan
High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis
title High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis
title_full High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis
title_fullStr High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis
title_full_unstemmed High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis
title_short High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis
title_sort high dose concentration administration of ascorbic acid inhibits tumor growth in balb/c mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732919/
https://www.ncbi.nlm.nih.gov/pubmed/19671184
http://dx.doi.org/10.1186/1479-5876-7-70
work_keys_str_mv AT yeomchanghwan highdoseconcentrationadministrationofascorbicacidinhibitstumorgrowthinbalbcmiceimplantedwithsarcoma180cancercellsviatherestrictionofangiogenesis
AT leegunsup highdoseconcentrationadministrationofascorbicacidinhibitstumorgrowthinbalbcmiceimplantedwithsarcoma180cancercellsviatherestrictionofangiogenesis
AT parkjinhee highdoseconcentrationadministrationofascorbicacidinhibitstumorgrowthinbalbcmiceimplantedwithsarcoma180cancercellsviatherestrictionofangiogenesis
AT yujaelim highdoseconcentrationadministrationofascorbicacidinhibitstumorgrowthinbalbcmiceimplantedwithsarcoma180cancercellsviatherestrictionofangiogenesis
AT parkseyeon highdoseconcentrationadministrationofascorbicacidinhibitstumorgrowthinbalbcmiceimplantedwithsarcoma180cancercellsviatherestrictionofangiogenesis
AT yisangyeop highdoseconcentrationadministrationofascorbicacidinhibitstumorgrowthinbalbcmiceimplantedwithsarcoma180cancercellsviatherestrictionofangiogenesis
AT leehyeree highdoseconcentrationadministrationofascorbicacidinhibitstumorgrowthinbalbcmiceimplantedwithsarcoma180cancercellsviatherestrictionofangiogenesis
AT hongyoungseon highdoseconcentrationadministrationofascorbicacidinhibitstumorgrowthinbalbcmiceimplantedwithsarcoma180cancercellsviatherestrictionofangiogenesis
AT yangjoosung highdoseconcentrationadministrationofascorbicacidinhibitstumorgrowthinbalbcmiceimplantedwithsarcoma180cancercellsviatherestrictionofangiogenesis
AT leesukchan highdoseconcentrationadministrationofascorbicacidinhibitstumorgrowthinbalbcmiceimplantedwithsarcoma180cancercellsviatherestrictionofangiogenesis